GammaCan International

GammaCan International Develops Immunotherapies for Treating Metastases and Other Cancers. Its Patented Platform Technology is Based on the Use of IgG (γ-Immunoglobulin), a Relatively Non-Toxic Human Plasma-Derived Product Used to Treat Various Immune Deficiencies and Autoimmune Diseases. The Company Offers VitiGam, a Second-Generation Intravenous IgG Product.